Announcement









                  Company Cambridge Antibody Tech Group PLC
                  TIDMCAT
                  Headline Offer Update
                  Released 07:01 24 Mar 2003
                  Number 0890J






03/CAT/10
      For further information contact:
      Cambridge Antibody Technology
      Tel: +44 (0) 1223 471 471
      Peter Chambre, Chief Executive Officer
      John Aston, Chief Financial Officer
      Rowena Gardner, Director of Corporate Communications
      Weber Shandwick Square Mile (Europe)
      Tel: +44 (0) 20 7067 0700
      Graham Herring


       BMC Communications/The Trout Group (USA)
      Tel: 001 212 477 9007
      Brad Miles, ext 17 (media)
      Brandon Lewis, ext.15 (investors)


CAT's Offer for OGS

Cambridge, UK: Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG)
notes the recent press reports that Celltech (LSE: CCH; NYSE: CLL) has
acquired approximately 10 per cent. of the outstanding share capital of
Oxford GlycoSciences (LSE: OGS; NASDAQ: OGSI).

CAT reminds OGS shareholders that the proposed merger of CAT and OGS
would be effected by way of a scheme of arrangement that would require
approval by a majority in number of the shareholders who vote at the
court convened meeting representing 75 per cent. of the shares voted
at that meeting. As a result, the proposed merger of CAT and OGS
can be achieved notwithstanding Celltech's recent acquisition of OGS
shares.

ENDS -

Notes to Editors
Cambridge Antibody Technology (CAT):
  CAT is a UK-based biotechnology company using its proprietary
  technologies and capabilities in human monoclonal antibodies for drug
  discovery and drug development. Based near Cambridge, England, CAT
  currently employs around 290 people.

  CAT is a leader in the discovery and development of human therapeutic
  antibodies and has an advanced proprietary platform technology for
  rapidly isolating human monoclonal antibodies using phage display
  systems. CAT has extensive phage antibody libraries, currently
  incorporating more than 100 billion distinct antibodies. These
  libraries form the basis for the Company's strategy to develop a
  portfolio of antibody-based drugs.

  HumiraTM is the leading CAT-derived antibody. Six other CAT-derived
  human therapeutic antibodies are at various stages of clinical trials.
  CAT has alliances with a large number of pharmaceutical and
  biotechnology companies to discover, develop and commercialise human
  monoclonal antibody-based products. CAT has also licensed its
  proprietary human phage antibody libraries to several companies for
  target validation and drug discovery. CAT's collaborators include:
  Abbott, Amgen, Amrad, Chugai, Elan, Genzyme, Human Genome Sciences,
  Merck & Co, Pharmacia and Wyeth Research.  CAT is listed on the
  London Stock Exchange and on NASDAQ since June 2001. CAT raised GBP41m
  in its IPO in March 1997 and GBP93m in a secondary offering in March
  2000.

Application of the Safe Harbor of the Private Securities Litigation
Reform Act of 1995:

This press release contains statements about Cambridge Antibody Technology
Group plc ("CAT") that are forward looking statements. All statements other
than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934. These forward looking statements are
based on numerous assumptions regarding CAT's present and future business
strategies and the environment in which CAT will operate in the future.
Certain factors hat could cause CAT's actual results, performance or
achievements to differ materially from those in the forward looking
statements include: market conditions, CAT's ability to enter into and
maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.
END